Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cybin Inc. Common Shares
(NY:
CYBN
)
6.170
+0.280 (+4.75%)
Official Closing Price
Updated: 8:00 PM EST, Nov 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc. Common Shares
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
41
42
Next >
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone
August 31, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
August 31, 2022
Via
Investor Brand Network
Topics
Death
Cybin Announces Final Adelia Milestone Achievement
August 31, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
↗
August 30, 2022
Cybin Inc.
Via
Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
↗
August 30, 2022
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business...
Via
Benzinga
Compass Pathways, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
August 30, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 2.83% at $1.09 LOSERS:
Via
Benzinga
7 Psychedelics Stocks to Buy for a Big Drug Boom
↗
August 30, 2022
These are the seven psychedelics stocks to buy in September. PSIL, ATAI, CMPS, CYBN, ENVB, GHRS and MNMD can make great investments
Via
InvestorPlace
BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD
August 30, 2022
Via
Investor Brand Network
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
August 30, 2022
From
Cybin Inc.
Via
Business Wire
Small Pharma, Biomind Labs Among Top Psychedelic Movers Of Today
↗
August 29, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 27.51% at $0.18
Via
Benzinga
How Psychedelics Startups Are Improving Their Resilience
August 29, 2022
Via
Investor Brand Network
Largest Psychedelic Compound-Based Drug Stocks On A Roll - Up 50% Since End Of June
↗
August 26, 2022
The Psychedelic Compounds-Based Drug Stocks Index went up 9.8% this week and is now up 49.5% since the end of June albeit down 32.6% YTD.
Via
Talk Markets
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
↗
August 26, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 3.61% at $1.00 LOSERS:
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector
August 26, 2022
Via
Investor Brand Network
Israeli Study identifies Bacterial Footprint in PTSD Sufferers
August 25, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference
August 25, 2022
Via
Investor Brand Network
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
From
Cybin Inc.
Via
Business Wire
Seelos Therapeutics, Mind Medicine Among Top Psychedelic Movers Of Today
↗
August 24, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 17.87% at $1.22
Via
Benzinga
How Meditation, Psychedelics Can Boost Healing
August 24, 2022
Via
Investor Brand Network
Psychedelic Stock Gainers And Losers From August 23, 2022
↗
August 23, 2022
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 5.33% at $14.24
Via
Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
↗
August 22, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 10.34% at $0.16
Via
Benzinga
FT-104: Field Trip’s Latest Psychedelic Drug Candidate
August 22, 2022
Via
Investor Brand Network
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
↗
August 19, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 29.35% at $0.14 LOSERS:
Via
Benzinga
Why Bed Bath & Beyond Is Trading Lower By Over 40%, Here Are 55 Stocks Moving In Friday's Mid-Day Session
↗
August 19, 2022
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 145% to $38.45 on continued volatility following the company's IPO on Thursday.
Via
Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
↗
August 18, 2022
Via
Benzinga
Study Suggests LSD May Boost Learning, Memory by Enhancing Neural Plasticity
August 18, 2022
Via
Investor Brand Network
Psychedelic Stock Gainers And Losers From August 17, 2022
↗
August 17, 2022
Via
Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Partner Receive Required Schedule I License from DEA for First-in-Human Clinical Trial
August 17, 2022
Via
Investor Brand Network
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
↗
August 17, 2022
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S.
Via
Benzinga
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
41
42
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today